tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Positive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR Mutations
PremiumRatingsPositive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR Mutations
2M ago
Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan Management
Premium
Ratings
Promising Drug Pipeline and Strategic Collaborations Drive Buy Rating for Cullinan Management
2M ago
Cullinan Management’s Strategic Adjustments and Pipeline Development Justify Buy Rating
Premium
Ratings
Cullinan Management’s Strategic Adjustments and Pipeline Development Justify Buy Rating
2M ago
Cullinan Management Updates Strategic Goals and Timeline
PremiumCompany AnnouncementsCullinan Management Updates Strategic Goals and Timeline
2M ago
Promising Developments in Cullinan Management’s Cancer Treatment Pipeline Drive Buy Rating
Premium
Ratings
Promising Developments in Cullinan Management’s Cancer Treatment Pipeline Drive Buy Rating
2M ago
Cullinan Therapeutics assumed with a Buy at H.C. Wainwright
Premium
The Fly
Cullinan Therapeutics assumed with a Buy at H.C. Wainwright
2M ago
Cullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating
PremiumRatingsCullinan Management: Strong Financials and Promising Pipeline Justify Buy Rating
3M ago
Cullinan Management Appoints New Board Members
Premium
Company Announcements
Cullinan Management Appoints New Board Members
3M ago
Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c)
Premium
The Fly
Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c)
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100